Poly Medicure (POLYMED)

FairStock Score: 62/100 — STEADY

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at Poly Medicure, I see a medical equipment supplier with a promoter holding of 62.42%, debt/equity of 0.11, ROCE of 20.08%, and an Altman Z-score of 4.27. That combination suggests a reasonably safe balance sheet and some competitive advantage, since a 20.08% ROCE is above what many commodity businesses earn. Sales are growing well: latest quarter sales were ₹494 Cr, net profit ₹71 Cr, reported sales growth is 30.30%, and the five-year revenue CAGR is 19.43%. The Piotroski F-Score of 7/9 also supports improving fundamentals. But the profit picture is mixed: profit growth is -7.50%, and ROE is 12.57%, so revenue is not dropping to the bottom line. More worrying, free cash flow is ₹-954 Cr; growth is consuming cash. Valuation is the biggest hurdle. At ₹1786.20, the P/E is 57.47, P/B is 5.83, EV/EBITDA is 28.46, and PEG is 7.98. Graham Number is ₹469.21, meaning the margin of safety is -167.71%. I would not call this a Graham bargain; the market is already pricing in a lot of future success. As Buffett might say, quality can be worth paying for, but not at any price. I would monitor profit growth, free cash flow, and whether sales growth continues without further balance-sheet strain. FairStock score of 62/100 labels it STEADY, which fits a decent but not obviously mispriced company. For now, it looks like a good business with a demanding price.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer